Enanta outlines 2026 milestones for RSV and immunology programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook
January 8, 2026 7:00 AM ESTContinuing Phase 3 Enabling Activities, Including Discussions with U.S. Food & Drug Administration (FDA) Following Positive Phase 2b RSVHR Results for Zelicapavir, an N-Protein Inhibitor in Development to Treat Respiratory Syncytial Virus (RSV) Expanding Immunology Pipeline with New Discovery Program Focused on MRGPRX2 Inhibition Addressing High Unmet Need in Chronic Spontaneous Urticaria (CSU); On Track to Select a Development Candidate in 2H 2026 Advancing EDP-978, an Oral, Once-Daily KIT Inhibitor Clinical Candidate; On Track to File an Investigational New Drug Application (IND) in 1Q 2026 and Report Phase 1 Data in 4Q 2026 Progressing... More
